Cedax (ceftibuten)
Company: Schering-Plough
Approval Status: Approved December 1995
Treatment for: chronic bronchitis, infection of the middle ear, pharyngitis/tonsillitis
Areas: Immunology/Infectious Diseases; Otolaryngology; Pulmonary/Respiratory Diseases
| General Information | Side Effects | Additional Information |
General Information
Clinical studies have demonstrated that Cedax is active against a broad spectrum of bacteria that are common causes of upper and lower respiratory tract infections. These include most strains of Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and Streptococcus pyogenes. Cedax is highly stable in the presence of beta-lactamases--enzymes produced by bacteria that can render some commonly used antibiotics, such as amoxicillin or penicillin, ineffective.
Side Effects
Clinical trials revealed a very low incidence of gastrointestinal side effects, including diarrhea.
Additional Information
Acute otitis media is the most commonly diagnosed infection among children today. By age three, 84 percent of all children will have experienced at least one episode of acute otitis media, and nearly 50 percent will have had three or more episodes.
Acute bacterial exacerbation of chronic bronchitis is a bacterial infection that frequently occurs in chronic bronchitis subjects. According to the American Lung Association, chronic bronchitis affects at least 13.8 million Americans.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
